Early trial of BL-M07D1 for advanced HER2-positive digestive tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This early-phase trial tests BL-M07D1 in people with advanced digestive tract (and other solid) cancers that can’t be removed with surgery and have already tried or can’t use standard treatment. It’s studying whether the drug works and how safe it is, and whether HER2 tumor results are linked to benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign consent and agree to follow the study plan.
- You’re at least 18 years old, and expected to live 3 months or more.
- Your cancer must be confirmed by tissue testing, with HER2 “high” or “low” results, and should not be operable; standard treatment must have failed or not be an option.
- Your scan must show at least one measurable tumor spot, and you should be able to care for yourself (ECOG 0–1).
- Your prior treatment side effects must be mostly back to normal (grade 0–1), and your blood counts, liver, kidneys, and clotting tests must be within required limits.
- You must be able to provide tumor tissue (archived or fresh) within 2 years, or your doctor must judge you can still join without it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called BL-M08D1 for people with solid tumors that have spread or cannot be removed by surgery and have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called BL-M07D1 for people with certain advanced solid tumors that have the HER2 protein (high or low amounts). The goal is to see if it can shrink or slow the growth of these cancers, especially in urinary and digestive system tumors.
This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
This trial tests a new drug called BL-M07D1 for women with HER2-positive or low-HER2 gynecologic cancers that have returned or spread. The drug is designed to target and kill cancer cells that make HER2, and may help when other treatments have stopped working.
This trial tests a new drug called BL-M17D1 for people with advanced or metastatic HER2-positive or low-expression gastrointestinal cancer and other solid tumors. The goal is to see if it is safe and effective.
Hear when a new Other Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.